Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14

Rhea-AI Summary

Biocept, Inc. (Nasdaq: BIOC) will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time). The presentation will feature insights from President and CEO Michael Nall and can be accessed here. Biocept specializes in molecular diagnostics for various cancers and has recently expanded into COVID-19 testing. For additional information, visit www.biocept.com.

News Market Reaction – BIOC

-10.18%

-10.18% Session move

In the trading session that priced this news, BIOC declined 10.18%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright 22^nd Annual Global Investment Conference on Monday, September 14, 2020 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time).

The live presentation can be accessed here and will be archived on the Investor Relations section of the Biocept website.

About Biocept 
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. In addition, Biocept recently added COVID-19 testing to support efforts to fight the pandemic. For additional information, please visit www.biocept.com.

Investor Contact: 
LHA Investor Relations  
Jody Cain 
Jcain@lhai.com 
310-691-7100

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-hc-wainwright-global-investment-virtual-conference-on-september-14-301126200.html

SOURCE Biocept, Inc.

FAQ

What is the date and time of Biocept's presentation at the H.C. Wainwright conference?

Biocept's presentation will take place on September 14, 2020, at 3:30 p.m. Eastern Time.

Who will present at the H.C. Wainwright conference for Biocept?

President and CEO Michael Nall will present at the conference.

Where can I access Biocept's presentation?

The presentation can be accessed here.

What services does Biocept provide?

Biocept provides molecular diagnostics for cancer and has recently added COVID-19 testing.

What is the stock symbol for Biocept?

Biocept is traded under the stock symbol BIOC.